Anavex Germany GmbH withdrew its application for a European marketing authorisation for Blarcamesine Anavex (blarcamesine) on 25 March 2026, and the European Medicines Agency has published the assessment it had reached before the file closed. The withdrawal is recorded in the agency's question-and-answer document and in the highlights of the Committee for Medicinal Products for Human Use (CHMP) meeting of 23 to 26 March 2026. The CHMP had adopted a negative opinion on 11 December 2025; the company requested a re-examination on 17 December 2025, according to a position paper published by Alzheimer Europe, then withdrew before that re-examination had finished. In its withdrawal letter, the company told the agency the decision was based on CHMP feedback that, on the basis of the data provided, it would not have been possible to conclude that the benefits of the medicine outweigh its risks.

The agency's document sets out the grounds. The main study presented was a randomised, placebo-controlled trial in 462 adults aged 60 to 85 with early Alzheimer's disease, measured over 48 weeks on two co-primary measures: cognition (ADAS-Cog13) and the ability to carry out daily activities (ADCS-ADL). The EMA concluded that the study did not meet its main objective, which was to show a smaller decline on both measures compared with placebo, and that the analysis had methodological issues raising concerns about the validity of the results. Given that failure and those issues, and on the basis of the analysis in the subgroup of patients without a mutation in the SIGMAR1 gene, the population the company had proposed during the evaluation, effectiveness could not be demonstrated. On safety, the agency noted that a high proportion of patients stopped treatment, mainly because of central nervous system side effects such as dizziness. On quality, it said the information provided did not allow the formation of nitrosamine impurities, which could potentially cause cancer, to be ruled out. The company had applied for a conditional marketing authorisation; the agency said the medicine did not meet the criteria for one, while recording that it acknowledged the unmet need in Alzheimer's disease and had taken account of the views of patients and health professionals.

Blarcamesine is a once-daily capsule that activates the sigma-1 receptor protein, and was proposed as an add-on treatment, without the infusions or the imaging monitoring that accompany the anti-amyloid antibodies. The trial results, published in The Journal of Prevention of Alzheimer's Disease on 1 January 2025, reported a difference favouring blarcamesine on ADAS-Cog13 of 2.027 points at 48 weeks (95% confidence interval 0.533 to 3.522; p = 0.008) and on the secondary measure CDR-SB of 0.483 points (p = 0.010), while ADCS-ADL did not reach significance (p = 0.357); 338 of the 462 participants in the intention-to-treat population, 73.2%, completed the trial. Alzheimer Europe, in a position adopted on 16 March 2026 and shared with CHMP members, said it understood the committee's view that the efficacy and safety data may have been insufficient for a full authorisation, but argued for a conditional authorisation instead.

For families in the European Union, the practical position is that there is no authorised blarcamesine and no pending application. The company said the agency had been informed that there are no consequences for patients in clinical trials or in compassionate use programmes. On 30 March 2026 Anavex said dialogue with the EMA continues on the early Alzheimer's programme, that additional data had been submitted to the United States Food and Drug Administration with the aim of discussing possible routes to a New Drug Application, and that it is in discussions with EU regulators about blarcamesine in Parkinson's disease and in rare diseases including Rett syndrome.